Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Nicolas Floc'h"'
Autor:
Jordi Bertran-Alamillo, Ana Giménez-Capitán, Ruth Román, Sara Talbot, Rebecca Whiteley, Nicolas Floc’h, Elizabeth Martínez-Pérez, Matthew J. Martin, Paul D. Smith, Ivana Sullivan, Mikkel G. Terp, Jamal Saeh, Cristina Marino-Buslje, Giulia Fabbri, Grace Guo, Man Xu, Cristian Tornador, Andrés Aguilar-Hernández, Noemí Reguart, Henrik J. Ditzel, Alejandro Martínez-Bueno, Núria Nabau-Moretó, Amaya Gascó, Rafael Rosell, J. Elizabeth Pease, Urszula M. Polanska, Jon Travers, Jelena Urosevic, Miguel A. Molina-Vila
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-24 (2023)
Abstract Background Drugs targeting the spindle assembly checkpoint (SAC), such as inhibitors of Aurora kinase B (AURKB) and dual specific protein kinase TTK, are in different stages of clinical development. However, cell response to SAC abrogation i
Externí odkaz:
https://doaj.org/article/0503e7da1cca40afa0953e96d2560af7
Autor:
Steven W. Criscione, Matthew J. Martin, Derek B. Oien, Aparna Gorthi, Ricardo J. Miragaia, Jingwen Zhang, Huawei Chen, Daniel L. Karl, Kerrin Mendler, Aleksandra Markovets, Sladjana Gagrica, Oona Delpuech, Jonathan R. Dry, Michael Grondine, Maureen M. Hattersley, Jelena Urosevic, Nicolas Floc’h, Lisa Drew, Yi Yao, Paul D. Smith
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-13 (2022)
Abstract Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, an irreversible EGFR-TKI, are important treatments for non-small cell lung cancer with EGFR-TKI sensitizing or EGFR T790M resistance mutations. While patien
Externí odkaz:
https://doaj.org/article/d7852854a3ba43459578c3fb424140e2
Autor:
Eric Tu, Kelly McGlinchey, Jixin Wang, Philip Martin, Steven L.K. Ching, Nicolas Floc’h, James Kurasawa, Jacqueline H. Starrett, Yelena Lazdun, Leslie Wetzel, Barrett Nuttall, Felicia S.L. Ng, Karen T. Coffman, Paul D. Smith, Katerina Politi, Zachary A. Cooper, Katie Streicher
Publikováno v:
JCI Insight, Vol 7, Iss 3 (2022)
Treatment with anti–PD-1 and anti-PD-L1 therapies has shown durable clinical benefit in non–small cell lung cancer (NSCLC). However, patients with NSCLC with epidermal growth factor receptor (EGFR) mutations do not respond as well to treatment as
Externí odkaz:
https://doaj.org/article/c6a5fda9646e49b8adcbb817d655948e
Autor:
Nicolas Floc'h, Maria Luisa Guerriero, Antonio Ramos-Montoya, Barry R. Davies, Jonathan Cairns, Natasha A. Karp
Publikováno v:
Disease Models & Mechanisms, Vol 11, Iss 11 (2018)
The high attrition rate of preclinical agents entering oncology clinical trials has been associated with poor understanding of the heterogeneous patient response, arising from limitations in the preclinical pipeline with cancer models. Patient-derive
Externí odkaz:
https://doaj.org/article/fbe31529bc76498fa1d09b256d8e05d0
Autor:
Yannick Simonin, Serena Vegna, Leila Akkari, Damien Grégoire, Etienne Antoine, Jacques Piette, Nicolas Floc'h, Patrice Lassus, Guann-Yi Yu, Arielle R Rosenberg, Michael Karin, David Durantel, Urszula Hibner
Publikováno v:
PLoS Pathogens, Vol 9, Iss 3, p e1003234 (2013)
Exposure to hepatitis C virus (HCV) typically results in chronic infection that leads to progressive liver disease ranging from mild inflammation to severe fibrosis and cirrhosis as well as primary liver cancer. HCV triggers innate immune signaling w
Externí odkaz:
https://doaj.org/article/aba6c2c467324ee39aea21eea458e347
Autor:
Nicolas Floc'h, Jakub Kolodziejski, Leila Akkari, Yannick Simonin, Stéphane Ansieau, Alain Puisieux, Urszula Hibner, Patrice Lassus
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e72490 (2013)
Expression of developmental genes Twist1 and Twist2 is reactivated in many human tumors. Among their oncogenic activities, induction of epithelial to mesenchymal transition is believed to increase cell motility and invasiveness and may be related to
Externí odkaz:
https://doaj.org/article/b2d23ee5fc534f148181b316840bb382
Autor:
Matthew J. Martin, Nicolas Floc'h, Matthias Pfeifer, Steven Criscione, Oona Delpuech, Sladjana Gagrica, Yi Yao, Ultan McDermott, Paul D. Smith
Publikováno v:
Cancer Research Communications. 2:1312-1325
Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) with proven clinical efficacy; however, acquired resistance presents an obstacle to curing EGFR-driven disease. Recent studies have shown that drug-tolerant persister cells (DTP) have a distinct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15fea425209752f7335dbf2128f0fcac
https://doi.org/10.1158/2767-9764.crc-22-0066
https://doi.org/10.1158/2767-9764.crc-22-0066
Autor:
Paul D. Smith, Ultan McDermott, Yi Yao, Sladjana Gagrica, Oona Delpuech, Steven Criscione, Matthias Pfeifer, Nicolas Floc'h, Matthew J. Martin
Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) with proven clinical efficacy; however, acquired resistance presents an obstacle to curing EGFR-driven disease. Recent studies have shown that drug-tolerant persister cells (DTP) have a distinct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40805deff71746b1716cde0e0b3ae320
https://doi.org/10.1158/2767-9764.c.6550875.v1
https://doi.org/10.1158/2767-9764.c.6550875.v1
Autor:
Paul D. Smith, Ultan McDermott, Yi Yao, Sladjana Gagrica, Oona Delpuech, Steven Criscione, Matthias Pfeifer, Nicolas Floc'h, Matthew J. Martin
Supplementary Table 1. Cell lines used. Supplementary Table 2. Antibodies used. Supplementary Figure S1. Osimertinib drug tolerant cells re-aquire apoptotic capacity after drug holiday. Supplementary Figure S2. BH3 mimetics can trigger apoptosis in e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6896ce50f7f95a7e25a4895b6be1d1f6
https://doi.org/10.1158/2767-9764.22545189
https://doi.org/10.1158/2767-9764.22545189
Autor:
Simon T. Barry, Elizabeth J. Pease, James E. Pilling, Nicola J. Curtis, Shenghua Wen, Maureen Hattersley, Vivien N. Jacobs, Jacqueline Caddy, Nicola Derbyshire, Kim Maratea, Rajesh Odedra, Emily Harris, Dawn Trueman, Paula Taylor, Susan Ashton, Nicolas Floc'h
Supplementary figues and tables: Figure S1. In vitro AZD1152-hQPA reduces proliferation and induces polyploidy across a panel of human AML cancer cell lines. Figure S2. AZD1152 has a modest effect on the growth of the HL-60 xenograft models in SCID m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04c1a017c2051488311435f1b1d1a91b
https://doi.org/10.1158/1535-7163.22503183
https://doi.org/10.1158/1535-7163.22503183